A win for Medicare patients and their wallets
The Inflation Reduction Act allows Medicare to negotiate drug prices and cap insulin costs...but only for Medicare enrollees. More
The Cerebral scandal brings ADHD overprescription into the spotlight
A telehealth company's downfall sheds light on the overprescription of stimulants to ADHD patients More
Why access to Aduhelm won’t improve health equity
After CMS restricted access to Aduhelm, Biogen and the Alzheimer's Association called the decision discriminatory. Here's why we're skeptical... More
What’s in the Congressional drug pricing report?
A recently-released Congressional committee report on drug prices reveals some outrageous business practices by pharma -- here's what they found. More
How a pharma-led campaign to lower a diabetes treatment target put seniors at risk
A recent Reuters investigation found that a campaign to lower the A1c target for diabetes was driven largely by pharmaceutical companies, to create a bigger market for their new blood sugar-lowering drugs. More
High-priced cancer drugs are driving pharma revenue
Has pharma cracked the secret code to profit through cancer drugs? A recent study takes a closer look at the impact of cancer drug prices on pharma revenues. More
Drug advertisements that scare
Despite larger health threats consuming the nation this year, pharma did not let up on their fear-mongering advertisements. Check out a few of the scariest-- if you dare! More
Is the price of remdesivir too high or too low?
Experts weigh in on the recently revealed price of Covid-19 drug remdesivir. More
Remdesivir report sparks more debate on drug price value
How much should remdesivir cost? This question puts two drug-value organizations at odds. More
Are high drug prices buying us the most effective treatments?
The pharmaceutical industry often justifies high drug prices by claiming that they create more innovation, but two recent studies find that drug costs and clinical benefit are often not related. More